THERANOSTIC METHOD FOR OPTIMIZING THE CHOICE OF AN IMMUNE CHECKPOINT BLOCKER TO BE ADMINISTERED TO A CANCER PATIENT

摘要

The present invention, pertains to the field of cancer therapy and provides predictive marker for determining if a patient suffering from metastatic melanoma or another cancer is likely to be a good responder to a treatment by Ipilimumab or another drug blocking an immune checkpoint.